Published in J Virol on March 01, 2005
Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med (2008) 4.57
Murine norovirus: a model system to study norovirus biology and pathogenesis. J Virol (2006) 3.91
Rapid evolution of pandemic noroviruses of the GII.4 lineage. PLoS Pathog (2010) 2.80
Adjuvanted intranasal Norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J Infect Dis (2010) 2.64
Viral shape-shifting: norovirus evasion of the human immune system. Nat Rev Microbiol (2010) 2.53
Determination of the 50% human infectious dose for Norwalk virus. J Infect Dis (2013) 2.50
The p domain of norovirus capsid protein forms a subviral particle that binds to histo-blood group antigen receptors. J Virol (2005) 2.29
Development of a microsphere-based serologic multiplexed fluorescent immunoassay and a reverse transcriptase PCR assay to detect murine norovirus 1 infection in mice. Clin Diagn Lab Immunol (2005) 2.25
Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog (2012) 2.02
The G428A nonsense mutation in FUT2 provides strong but not absolute protection against symptomatic GII.4 Norovirus infection. PLoS One (2009) 1.89
Norovirus GII.4 strain antigenic variation. J Virol (2010) 1.73
Noroviruses: The leading cause of gastroenteritis worldwide. Discov Med (2010) 1.73
Norovirus-host interaction: multi-selections by human histo-blood group antigens. Trends Microbiol (2011) 1.73
Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol (2009) 1.70
Pathogenesis and immune responses in gnotobiotic calves after infection with the genogroup II.4-HS66 strain of human norovirus. J Virol (2007) 1.70
Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. PLoS Pathog (2008) 1.69
Antibody is critical for the clearance of murine norovirus infection. J Virol (2008) 1.69
Pathogenesis of noroviruses, emerging RNA viruses. Viruses (2010) 1.67
Genetic diversity and histo-blood group antigen interactions of rhesus enteric caliciviruses. J Virol (2010) 1.61
Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J Virol (2009) 1.51
Comprehensive review of human sapoviruses. Clin Microbiol Rev (2015) 1.48
Genetic and phenotypic characterization of GII-4 noroviruses that circulated during 1987 to 2008. J Virol (2010) 1.46
Advances in norovirus biology. Cell Host Microbe (2014) 1.45
Norovirus. Clin Microbiol Rev (2015) 1.41
Norovirus immunity and the great escape. PLoS Pathog (2012) 1.40
Noroviruses - State of the Art. Food Environ Virol (2010) 1.39
Duration of immunity to norovirus gastroenteritis. Emerg Infect Dis (2013) 1.38
Norovirus gastroenteritis outbreak with a secretor-independent susceptibility pattern, Sweden. Emerg Infect Dis (2010) 1.32
Cytokine and antibody responses in gnotobiotic pigs after infection with human norovirus genogroup II.4 (HS66 strain). J Virol (2007) 1.31
Norovirus infectivity in humans and persistence in water. Appl Environ Microbiol (2011) 1.26
The effects of simvastatin or interferon-α on infectivity of human norovirus using a gnotobiotic pig model for the study of antivirals. PLoS One (2012) 1.18
Characterization of emerging GII.g/GII.12 noroviruses from a gastroenteritis outbreak in the United States in 2010. J Clin Microbiol (2011) 1.18
Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J Virol (2009) 1.17
Asymptomatic norovirus infection in Mexican children. J Clin Microbiol (2006) 1.13
A comparison of immunogenicity of norovirus GII-4 virus-like particles and P-particles. Immunology (2012) 1.12
Critical review of norovirus surrogates in food safety research: rationale for considering volunteer studies. Food Environ Virol (2011) 1.10
Experimental inoculation of juvenile rhesus macaques with primate enteric caliciviruses. PLoS One (2012) 1.10
Broad blockade antibody responses in human volunteers after immunization with a multivalent norovirus VLP candidate vaccine: immunological analyses from a phase I clinical trial. PLoS Med (2015) 1.09
The viral polymerase inhibitor 2'-C-methylcytidine inhibits Norwalk virus replication and protects against norovirus-induced diarrhea and mortality in a mouse model. J Virol (2013) 1.05
Persistent enteric murine norovirus infection is associated with functionally suboptimal virus-specific CD8 T cell responses. J Virol (2013) 1.05
Host genetic factors affect susceptibility to norovirus infections in Burkina Faso. PLoS One (2013) 1.04
Trivalent combination vaccine induces broad heterologous immune responses to norovirus and rotavirus in mice. PLoS One (2013) 1.02
Norovirus Infection and Disease in an Ecuadorian Birth Cohort: Association of Certain Norovirus Genotypes With Host FUT2 Secretor Status. J Infect Dis (2014) 1.01
Characterization of blockade antibody responses in GII.2.1976 Snow Mountain virus-infected subjects. J Virol (2013) 0.98
Glycosphingolipids as receptors for non-enveloped viruses. Viruses (2010) 0.98
Model systems for the study of human norovirus Biology. Future Virol (2009) 0.97
Antibody responses to norovirus genogroup GI.1 and GII.4 proteases in volunteers administered Norwalk virus. Clin Vaccine Immunol (2012) 0.97
Mucosal and Cellular Immune Responses to Norwalk Virus. J Infect Dis (2015) 0.96
Deep sequencing of norovirus genomes defines evolutionary patterns in an urban tropical setting. J Virol (2014) 0.94
Median infectious dose of human norovirus GII.4 in gnotobiotic pigs is decreased by simvastatin treatment and increased by age. J Gen Virol (2013) 0.91
Identification of cross-reactive norovirus CD4+ T cell epitopes. J Virol (2010) 0.91
Gangliosides are ligands for human noroviruses. J Am Chem Soc (2014) 0.90
Two gastroenteritis outbreaks caused by GII Noroviruses: host susceptibility and HBGA phenotypes. PLoS One (2013) 0.89
Newcastle disease virus vector producing human norovirus-like particles induces serum, cellular, and mucosal immune responses in mice. J Virol (2014) 0.87
Transient or persistent norovirus infection does not alter the pathology of Salmonella typhimurium induced intestinal inflammation and fibrosis in mice. Comp Immunol Microbiol Infect Dis (2011) 0.87
Long-term inactivation study of three enteroviruses in artificial surface and groundwaters, using PCR and cell culture. Appl Environ Microbiol (2008) 0.87
Norovirus immunology: Of mice and mechanisms. Eur J Immunol (2015) 0.85
Experimental human infection with Norwalk virus elicits a surrogate neutralizing antibody response with cross-genogroup activity. Clin Vaccine Immunol (2014) 0.84
Structural Constraints on Human Norovirus Binding to Histo-Blood Group Antigens. mSphere (2016) 0.84
Genetic susceptibility to norovirus GII.3 and GII.4 infections in Chinese pediatric diarrheal disease. Pediatr Infect Dis J (2014) 0.84
Intranasal P particle vaccine provided partial cross-variant protection against human GII.4 norovirus diarrhea in gnotobiotic pigs. J Virol (2014) 0.83
Innate Resistance and Susceptibility to Norovirus Infection. PLoS Pathog (2016) 0.81
Kinetics of transmission, infectivity, and genome stability of two novel mouse norovirus isolates in breeding mice. Comp Med (2009) 0.81
Vitamin A modifies the intestinal chemokine and cytokine responses to norovirus infection in Mexican children. J Nutr (2011) 0.81
Vaccine against norovirus. Hum Vaccin Immunother (2014) 0.79
Benign Rabbit Caliciviruses Exhibit Evolutionary Dynamics Similar to Those of Their Virulent Relatives. J Virol (2016) 0.78
Vomiting as a Symptom and Transmission Risk in Norovirus Illness: Evidence from Human Challenge Studies. PLoS One (2016) 0.78
Human norovirus infection and the acute serum cytokine response. Clin Exp Immunol (2015) 0.78
Immunogenicity of Newcastle disease virus vectors expressing Norwalk virus capsid protein in the presence or absence of VP2 protein. Virology (2015) 0.77
Immunocompetent adults from human norovirus challenge studies do not exhibit norovirus viremia. J Virol (2015) 0.77
Norovirus in symptomatic and asymptomatic individuals: cytokines and viral shedding. Clin Exp Immunol (2016) 0.76
Replication of Human Norovirus RNA in Mammalian Cells Reveals Lack of Interferon Response. J Virol (2016) 0.76
Application of salivary antibody immunoassays for the detection of incident infections with Norwalk virus in a group of volunteers. J Immunol Methods (2015) 0.76
Norovirus-Specific Memory T Cell Responses in Adult Human Donors. Front Microbiol (2016) 0.75
Pattern of activation of human antigen presenting cells by genotype GII.4 norovirus virus-like particles. J Transl Med (2013) 0.75
Norovirus vaccines: Correlates of protection, challenges and limitations. Hum Vaccin Immunother (2016) 0.75
Capturing the systemic immune signature of a norovirus infection: an n-of-1 case study within a clinical trial. Wellcome Open Res (2017) 0.75
Use of Pathogen-Specific Antibody Biomarkers to Estimate Waterborne Infections in Population-Based Settings. Curr Environ Health Rep (2016) 0.75
Expression, self-assembly, and antigenicity of the Norwalk virus capsid protein. J Virol (1992) 8.35
Human susceptibility and resistance to Norwalk virus infection. Nat Med (2003) 7.07
Original antigenic sin and apoptosis in the pathogenesis of dengue hemorrhagic fever. Nat Med (2003) 6.25
Molecular epidemiology of "Norwalk-like viruses" in outbreaks of gastroenteritis in the United States. J Infect Dis (1998) 5.32
Norwalk virus infection and disease is associated with ABO histo-blood group type. J Infect Dis (2002) 5.09
Epidemiologic and molecular trends of "Norwalk-like viruses" associated with outbreaks of gastroenteritis in the United States. J Infect Dis (2002) 4.88
Clinical immunity in acute gastroenteritis caused by Norwalk agent. N Engl J Med (1977) 4.80
Norwalk virus infection of volunteers: new insights based on improved assays. J Infect Dis (1994) 4.37
Norwalk virus binds to histo-blood group antigens present on gastroduodenal epithelial cells of secretor individuals. Gastroenterology (2002) 4.13
Noroviruses bind to human ABO, Lewis, and secretor histo-blood group antigens: identification of 4 distinct strain-specific patterns. J Infect Dis (2003) 4.03
Transmission of acute infectious nonbacterial gastroenteritis to volunteers by oral administration of stool filtrates. J Infect Dis (1971) 3.88
Detection and differentiation of antigenically distinct small round-structured viruses (Norwalk-like viruses) by reverse transcription-PCR and southern hybridization. J Clin Microbiol (1995) 3.69
Norwalk virus-like particle hemagglutination by binding to h histo-blood group antigens. J Virol (2003) 3.15
Comparison of three agents of acute infectious nonbacterial gastroenteritis by cross-challenge in volunteers. J Infect Dis (1974) 3.10
Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol (2002) 2.98
Genetic polymorphism across regions of the three open reading frames of "Norwalk-like viruses". Arch Virol (2000) 2.84
Correlation of patient immune responses with genetically characterized small round-structured viruses involved in outbreaks of nonbacterial acute gastroenteritis in the United States, 1990 to 1995. J Med Virol (1997) 2.70
Multiple-challenge study of host susceptibility to Norwalk gastroenteritis in US adults. J Infect Dis (1990) 2.63
Recombinant Norwalk virus-like particles given orally to volunteers: phase I study. Gastroenterology (1999) 2.54
Expression, self-assembly, and antigenicity of a snow mountain agent-like calicivirus capsid protein. J Clin Microbiol (1995) 2.43
A predominant role for Norwalk-like viruses as agents of epidemic gastroenteritis in Maryland nursing homes for the elderly. J Infect Dis (2002) 2.33
Application of PCR to detect Norwalk virus in fecal specimens from outbreaks of gastroenteritis. J Clin Microbiol (1994) 2.27
Th1- and Th2-cell commitment during infectious disease: asymmetry in divergent pathways. Trends Immunol (2001) 2.26
Detection by immune electron microscopy of the Snow Mountain agent of acute viral gastroenteritis. J Infect Dis (1982) 2.26
Systematic and intestinal antibody-secreting cell responses and correlates of protective immunity to human rotavirus in a gnotobiotic pig model of disease. J Virol (1996) 2.25
Human cytotoxic T-lymphocyte repertoire to influenza A viruses. J Virol (1998) 2.10
Outbreaks of gastroenteritis associated with noroviruses on cruise ships--United States, 2002. MMWR Morb Mortal Wkly Rep (2002) 1.92
Humoral, mucosal, and cellular immune responses to oral Norwalk virus-like particles in volunteers. Clin Immunol (2003) 1.89
Expression and self-assembly of norwalk virus capsid protein from venezuelan equine encephalitis virus replicons. J Virol (2002) 1.60
Rhinovirus-induced interferon-gamma and airway responsiveness in asthma. Am J Respir Crit Care Med (2003) 1.57
HIV antigens can induce TGF-beta(1)-producing immunoregulatory CD8+ T cells. J Immunol (2002) 1.55
Viral shedding and fecal IgA response after Norwalk virus infection. J Infect Dis (1995) 1.41
Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles. J Infect Dis (2003) 1.40
Dynamics of memory T cell proliferation under conditions of heterologous immunity and bystander stimulation. J Immunol (2002) 1.35
Antibody-secreting cell responses and protective immunity assessed in gnotobiotic pigs inoculated orally or intramuscularly with inactivated human rotavirus. J Virol (1998) 1.33
Homologous versus heterologous immune responses to Norwalk-like viruses among crew members after acute gastroenteritis outbreaks on 2 US Navy vessels. J Infect Dis (2002) 1.26
Dengue-specific T cell responses in peripheral blood mononuclear cells obtained prior to secondary dengue virus infections in Thai schoolchildren. J Infect Dis (2002) 1.26
Identification of three HLA-A*0201-restricted cytotoxic T cell epitopes in the cytomegalovirus protein pp65 that are conserved between eight strains of the virus. J Immunol (1999) 1.20
Homotypic and heterotypic IgG and IgM antibody responses in adults infected with small round structured viruses. J Med Virol (1998) 1.20
Frequencies of virus-specific CD4(+) and CD8(+) T lymphocytes secreting gamma interferon after acute natural rotavirus infection in children and adults. J Virol (2002) 1.17
Immunity to calicivirus infection. J Infect Dis (2000) 1.17
Mucosal and systemic immune activation is present in human immunodeficiency virus-exposed seronegative women. J Infect Dis (2000) 1.09
T helper cell-mediated in vitro responses of recently and remotely infected subjects to a candidate recombinant vaccine for human parvovirus b19. J Infect Dis (2001) 1.03
Beyond 51Cr release: New methods for assessing HIV-1-specific CD8+ T cell responses in peripheral blood and mucosal tissues. Clin Exp Immunol (2002) 1.00
Immediate-early transactivator Rta of Epstein-Barr virus (EBV) shows multiple epitopes recognized by EBV-specific cytotoxic T lymphocytes. J Virol (1998) 0.98
Presentation and binding affinity of equine infectious anemia virus CTL envelope and matrix protein epitopes by an expressed equine classical MHC class I molecule. J Immunol (2003) 0.97
Cellular immunity to human immunodeficiency virus type 1 (HIV-1) clades: relevance to HIV-1 vaccine trials in Uganda. J Infect Dis (2000) 0.97
Control of lymphocytic choriomeningitis virus infection in granzyme B deficient mice. Virology (2003) 0.94
Functional mapping of protective epitopes within the rotavirus VP6 protein in mice belonging to different haplotypes. Vaccine (2003) 0.90
Antibody prevalence and immunoglobulin IgG subclass pattern to Norwalk virus in Sweden. J Med Virol (1995) 0.89
Immunoglobulin M antibody test to detect genogroup II Norwalk-like virus infection. J Clin Microbiol (1999) 0.83
Human susceptibility and resistance to Norwalk virus infection. Nat Med (2003) 7.07
Middle East respiratory syndrome coronavirus (MERS-CoV): announcement of the Coronavirus Study Group. J Virol (2013) 4.98
Serum antibody responses after intradermal vaccination against influenza. N Engl J Med (2004) 4.88
Mechanisms of GII.4 norovirus persistence in human populations. PLoS Med (2008) 4.57
Mercury concentrations and metabolism in infants receiving vaccines containing thiomersal: a descriptive study. Lancet (2002) 4.55
Systematic assembly of a full-length infectious cDNA of mouse hepatitis virus strain A59. J Virol (2002) 4.29
Norwalk virus: how infectious is it? J Med Virol (2008) 3.93
Genetic analysis of complex traits in the emerging Collaborative Cross. Genome Res (2011) 3.25
Efficacy of an acellular pertussis vaccine among adolescents and adults. N Engl J Med (2005) 3.21
Binding of Norwalk virus-like particles to ABH histo-blood group antigens is blocked by antisera from infected human volunteers or experimentally vaccinated mice. J Virol (2002) 2.98
Reverse genetics with a full-length infectious cDNA of severe acute respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2003) 2.82
Induction of tumor cell apoptosis in vivo increases tumor antigen cross-presentation, cross-priming rather than cross-tolerizing host tumor-specific CD8 T cells. J Immunol (2003) 2.81
Recombination, reservoirs, and the modular spike: mechanisms of coronavirus cross-species transmission. J Virol (2009) 2.60
Infected-host-cell repertoire and cellular response in the lung following inhalation of Francisella tularensis Schu S4, LVS, or U112. Infect Immun (2008) 2.53
Viral shape-shifting: norovirus evasion of the human immune system. Nat Rev Microbiol (2010) 2.53
Recovery of drug-resistant influenza virus from immunocompromised patients: a case series. J Infect Dis (2006) 2.43
Identification of human neutralizing antibodies that bind to complex epitopes on dengue virions. Proc Natl Acad Sci U S A (2012) 2.42
Efficacy of high-dose versus standard-dose influenza vaccine in older adults. N Engl J Med (2014) 2.27
Severe acute respiratory syndrome coronavirus group-specific open reading frames encode nonessential functions for replication in cell cultures and mice. J Virol (2005) 2.22
Severe acute respiratory syndrome coronavirus ORF6 antagonizes STAT1 function by sequestering nuclear import factors on the rough endoplasmic reticulum/Golgi membrane. J Virol (2007) 2.18
Rapid generation of a mouse model for Middle East respiratory syndrome. Proc Natl Acad Sci U S A (2014) 2.17
Severe acute respiratory syndrome coronavirus infection of human ciliated airway epithelia: role of ciliated cells in viral spread in the conducting airways of the lungs. J Virol (2005) 2.05
Immunogenetic mechanisms driving norovirus GII.4 antigenic variation. PLoS Pathog (2012) 2.02
Synthetic recombinant bat SARS-like coronavirus is infectious in cultured cells and in mice. Proc Natl Acad Sci U S A (2008) 1.97
Norovirus pathogenesis: mechanisms of persistence and immune evasion in human populations. Immunol Rev (2008) 1.96
A decade after SARS: strategies for controlling emerging coronaviruses. Nat Rev Microbiol (2013) 1.94
Heterologous gene expression from transmissible gastroenteritis virus replicon particles. J Virol (2002) 1.85
Bordetella Pertussis infections in vaccinated and unvaccinated adolescents and adults, as assessed in a national prospective randomized Acellular Pertussis Vaccine Trial (APERT). Clin Infect Dis (2006) 1.83
Phase 1 trial of AMA1-C1/Alhydrogel plus CPG 7909: an asexual blood-stage vaccine for Plasmodium falciparum malaria. PLoS One (2008) 1.81
Norovirus capture with histo-blood group antigens reveals novel virus-ligand interactions. J Virol (2004) 1.80
Mercury levels in newborns and infants after receipt of thimerosal-containing vaccines. Pediatrics (2008) 1.79
Unique signatures of long noncoding RNA expression in response to virus infection and altered innate immune signaling. MBio (2010) 1.79
Simulation and prediction of the adaptive immune response to influenza A virus infection. J Virol (2009) 1.76
Severe acute respiratory syndrome coronavirus evades antiviral signaling: role of nsp1 and rational design of an attenuated strain. J Virol (2007) 1.75
Evidence supporting a zoonotic origin of human coronavirus strain NL63. J Virol (2012) 1.75
Multivalent norovirus vaccines induce strong mucosal and systemic blocking antibodies against multiple strains. Vaccine (2006) 1.74
Norovirus GII.4 strain antigenic variation. J Virol (2010) 1.73
Reverse genetics with a full-length infectious cDNA of the Middle East respiratory syndrome coronavirus. Proc Natl Acad Sci U S A (2013) 1.73
Epidemiology and drinking water: are we running dry? Epidemiology (2003) 1.73
The nsp2 replicase proteins of murine hepatitis virus and severe acute respiratory syndrome coronavirus are dispensable for viral replication. J Virol (2005) 1.71
Heterotypic humoral and cellular immune responses following Norwalk virus infection. J Virol (2009) 1.70
Immune mechanisms responsible for vaccination against and clearance of mucosal and lymphatic norovirus infection. PLoS Pathog (2008) 1.69
Antibody is critical for the clearance of murine norovirus infection. J Virol (2008) 1.69
Tropism of and innate immune responses to the novel human betacoronavirus lineage C virus in human ex vivo respiratory organ cultures. J Virol (2013) 1.68
Infidelity of SARS-CoV Nsp14-exonuclease mutant virus replication is revealed by complete genome sequencing. PLoS Pathog (2010) 1.67
Respiratory Francisella tularensis live vaccine strain infection induces Th17 cells and prostaglandin E2, which inhibits generation of gamma interferon-positive T cells. Infect Immun (2008) 1.66
Immune responses and antibody decay after immunization of adolescents and adults with an acellular pertussis vaccine: the APERT Study. J Infect Dis (2004) 1.60
Impact of a school-based hygiene promotion and sanitation intervention on pupil hand contamination in Western Kenya: a cluster randomized trial. Am J Trop Med Hyg (2012) 1.60
Severe acute respiratory syndrome coronavirus papain-like protease ubiquitin-like domain and catalytic domain regulate antagonism of IRF3 and NF-kappaB signaling. J Virol (2009) 1.58
Natural strain variation and antibody neutralization of dengue serotype 3 viruses. PLoS Pathog (2010) 1.56
HIV antigens can induce TGF-beta(1)-producing immunoregulatory CD8+ T cells. J Immunol (2002) 1.55
CD8+ T cell activation is governed by TCR-peptide/MHC affinity, not dissociation rate. J Immunol (2007) 1.54
Single-amino-acid substitutions in open reading frame (ORF) 1b-nsp14 and ORF 2a proteins of the coronavirus mouse hepatitis virus are attenuating in mice. J Virol (2005) 1.54
Genetic mapping of a highly variable norovirus GII.4 blockade epitope: potential role in escape from human herd immunity. J Virol (2011) 1.53
Herd immunity to GII.4 noroviruses is supported by outbreak patient sera. J Virol (2009) 1.51
Emergence of new pandemic GII.4 Sydney norovirus strain correlates with escape from herd immunity. J Infect Dis (2013) 1.47
MyD88 is required for protection from lethal infection with a mouse-adapted SARS-CoV. PLoS Pathog (2008) 1.47
Recent advances in our understanding of the environmental, epidemiological, immunological, and clinical dimensions of coccidioidomycosis. Clin Microbiol Rev (2013) 1.44
CD4-CD8- T cells control intracellular bacterial infections both in vitro and in vivo. J Exp Med (2005) 1.44
Peak frequencies of circulating human influenza-specific antibody secreting cells correlate with serum antibody response after immunization. Vaccine (2010) 1.43
Modeling host genetic regulation of influenza pathogenesis in the collaborative cross. PLoS Pathog (2013) 1.43
Peripheral "CD8 tuning" dynamically modulates the size and responsiveness of an antigen-specific T cell pool in vivo. J Immunol (2005) 1.42
Cell host response to infection with novel human coronavirus EMC predicts potential antivirals and important differences with SARS coronavirus. MBio (2013) 1.41
Cynomolgus macaque as an animal model for severe acute respiratory syndrome. PLoS Med (2006) 1.40
Norovirus immunity and the great escape. PLoS Pathog (2012) 1.40
Francisella tularensis-infected macrophages release prostaglandin E2 that blocks T cell proliferation and promotes a Th2-like response. J Immunol (2007) 1.39
Emergence of a norovirus GII.4 strain correlates with changes in evolving blockade epitopes. J Virol (2012) 1.36
Systemic, mucosal, and heterotypic immune induction in mice inoculated with Venezuelan equine encephalitis replicons expressing Norwalk virus-like particles. J Virol (2002) 1.36
Expression quantitative trait Loci for extreme host response to influenza a in pre-collaborative cross mice. G3 (Bethesda) (2012) 1.35
Lung CD4-CD8- double-negative T cells are prominent producers of IL-17A and IFN-gamma during primary respiratory murine infection with Francisella tularensis live vaccine strain. J Immunol (2010) 1.34
SARS coronavirus pathogenesis: host innate immune responses and viral antagonism of interferon. Curr Opin Virol (2012) 1.33
Cleavage between replicase proteins p28 and p65 of mouse hepatitis virus is not required for virus replication. J Virol (2004) 1.32
SARS-CoV pathogenesis is regulated by a STAT1 dependent but a type I, II and III interferon receptor independent mechanism. PLoS Pathog (2010) 1.32
Monoclonal antibody-based antigenic mapping of norovirus GII.4-2002. J Virol (2011) 1.29
Safety and immunogenicity of a trivalent, inactivated, mammalian cell culture-derived influenza vaccine in healthy adults, seniors, and children. Vaccine (2002) 1.29
Interplay between TCR affinity and necessity of coreceptor ligation: high-affinity peptide-MHC/TCR interaction overcomes lack of CD8 engagement. J Immunol (2003) 1.27
Prevalence of antibody to Bordetella pertussis antigens in serum specimens obtained from 1793 adolescents and adults. Clin Infect Dis (2004) 1.27
A live, impaired-fidelity coronavirus vaccine protects in an aged, immunocompromised mouse model of lethal disease. Nat Med (2012) 1.26
Norovirus infectivity in humans and persistence in water. Appl Environ Microbiol (2011) 1.26
Efficacy and tolerability of the oral neuraminidase inhibitor peramivir in experimental human influenza: randomized, controlled trials for prophylaxis and treatment. Antivir Ther (2005) 1.24
Evaluation of serologic and antigenic relationships between middle eastern respiratory syndrome coronavirus and other coronaviruses to develop vaccine platforms for the rapid response to emerging coronaviruses. J Infect Dis (2013) 1.23
Systematic assembly of a full-length infectious clone of human coronavirus NL63. J Virol (2008) 1.23
Characterization of the homo- and heterotypic immune responses after natural norovirus infection. J Med Virol (2005) 1.23
Processing of open reading frame 1a replicase proteins nsp7 to nsp10 in murine hepatitis virus strain A59 replication. J Virol (2007) 1.22
Rewiring the severe acute respiratory syndrome coronavirus (SARS-CoV) transcription circuit: engineering a recombination-resistant genome. Proc Natl Acad Sci U S A (2006) 1.22
Retracted Dengue virus envelope protein domain I/II hinge determines long-lived serotype-specific dengue immunity. Proc Natl Acad Sci U S A (2014) 1.19
Characterization of emerging GII.g/GII.12 noroviruses from a gastroenteritis outbreak in the United States in 2010. J Clin Microbiol (2011) 1.18
Coronaviruses: an RNA proofreading machine regulates replication fidelity and diversity. RNA Biol (2011) 1.18
Alphavirus-adjuvanted norovirus-like particle vaccines: heterologous, humoral, and mucosal immune responses protect against murine norovirus challenge. J Virol (2009) 1.17
Improved quality control processing of peptide-centric LC-MS proteomics data. Bioinformatics (2011) 1.15
Crystal structure of the receptor-binding domain from newly emerged Middle East respiratory syndrome coronavirus. J Virol (2013) 1.15
Vaccination of macaques with SIV immunogens delivered by Venezuelan equine encephalitis virus replicon particle vectors followed by a mucosal challenge with SIVsmE660. Vaccine (2005) 1.14
Effectiveness of liquid soap and hand sanitizer against Norwalk virus on contaminated hands. Appl Environ Microbiol (2009) 1.14
Development and characterization of a reverse genetic system for studying dengue virus serotype 3 strain variation and neutralization. PLoS Negl Trop Dis (2012) 1.14
Novel influenza virus NS1 antagonists block replication and restore innate immune function. J Virol (2008) 1.11
Mouse dipeptidyl peptidase 4 is not a functional receptor for Middle East respiratory syndrome coronavirus infection. J Virol (2014) 1.11
FluBlok, a recombinant hemagglutinin influenza vaccine. Influenza Other Respir Viruses (2008) 1.10